Sony's latest PlayStation live stream has come to an end and we've gathered all of the news and trailers from the event today. The September Sony State of Play yesterday focused on updates about ...

Strip the types and hotwire the HTML—and triple check your package security while you are at it. JavaScript in 2026 is just getting started. I am loath to inform you that the first month of 2026 has ...

React conquered XSS? Think again. That's the reality facing JavaScript developers in 2025, where attackers have quietly evolved their injection techniques to exploit everything from prototype ...

Pew Research Center conducted this study to better understand which voters cast ballots in the 2024 presidential election and how they voted. We also wanted to compare how turnout and vote choices ...

Cisco subsidiary ThousandEyes released its list of the most notable Internet outages and application issues of last year, along with recommendations to help ITOps teams improve digital resilience.

Health care and government were the two sectors that saw the most job growth in both 2024 and 2023. But a second Trump administration may pose risks to growth in both areas. Conversely, Trump's ...

We issues alerts in many instances when the Climate Shift Index identifies a notable extreme weather event around the world that was made more likely by human-caused climate change. Climate Matters is ...

Crude oil markets experienced limited activity over the past week as the holiday season reduced trading volumes. With markets closed for New Year’s Day, price movement was minimal, reflecting the lack ...

For stock investors, 2024 was an expectedly great year. Behind the continued bull market for stocks was solid economic growth, falling inflation, Federal Reserve interest-rate cuts, and healthy ...

Amid another year of solid performance in the stock market, AppLovin APP performed best in the Morningstar US Large-Mid Cap Index. The mobile app technology company surged over 700% in 2024 after ...

The FDA’s Center for Drug Evaluation and Research (CDER) approved 50 new small molecules, biologics and oligonucleotide therapeutics last year. The class of 2024 was a little smaller than that of 2023 ...